Societies and clinicians need to understand economic concepts and be able to contribute positively to economic PD 332991 evaluations [44]. We should not allow health economists to be the sole influence on Governments on the availability of new therapy or the maintenance or introduction of treatment regimens such as prophylaxis. It is our responsibility

as a patient community to make a contribution to these vital decisions. To do this effectively, we must be able to demonstrate the efficacy of treatment or treatment regimens using outcome data. Across the developed world there is significant variation in national funding arrangements for the treatment of haemophilia and the resulting outcomes [36]. Haemophilia care in Australia is at the upper end of funding levels and effectiveness for patients. Funding of haemophilia care in Australia is supported by a unique collaborative partnership between governments, healthcare providers and people with haemophilia to deliver a highly effective model of care. Although governments provide the majority of direct and indirect health funding to support people with haemophilia, this is within a framework of shared responsibility Acalabrutinib that recognizes the high per capita cost of this area of healthcare. In product costs alone, Australian

governments provided funding in 2013/2014 in the order of $A170 million, representing approximately 18% of the total budget for all blood 上海皓元 and blood products. This significant funding contribution is balanced by the active involvement of healthcare providers and people with haemophilia to ensure every dollar spent delivers greatest effect. This presentation outlines the Australian arrangements for supporting provision of effective care for haemophilia. In identifying the elements of these arrangements, the presentation highlights the potential benefits still to be obtained in Australia from consistent collection and recording of nationally agreed outcome measures. Australian

Funding Arrangements for the treatment of people with haemophilia consist of two main elements. The supply of product and a national framework to support improvements in clinical practice are funded under legislated National Blood Arrangements. The arrangements for delivery of care are funded by the Commonwealth and jurisdictional governments under the separate general provisions of the recently introduced National Health Reform. Under the National Blood Arrangements, the Australian Government provides 63% funding and 37% is collectively provided by state and territory governments. The National Blood Authority (NBA) is the Australian Government statutory agency that that manages the funding and represents the interests of the Australian, state and territory governments in relation to the supply of blood and blood products.